Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

Anti-VEGF agents in the treatment of diabetic macular edema

Cover Page

Abstract


Diabetic macular edema (DME) is a common complication associated with the loss of visual acuity in diabetic patients. Intravitreal injections of vascular endothelium growth factor (VEGF) inhibitors (anti-VEGF therapy) have been proposed recently as a new treatment option for patients with DME. In this review we summarized results of randomized clinical trials of VEGF inhibitors in DME patients. The results indicate that all studied inhibitors (ranibizumab, bevacizumab, pegaptanib and aflibersept) reduce the retinal thickness and improve of visual acuity in DME when are used as a monotherapy or in combination with the laser treatment. Optimal course duration and effectiveness predictors of anti-VEGF therapy in DME should be elucidate in the future studies.

Vladimir Iosifovich Konenkov

Research Institute of Clinical and Experimental Lymphology, Novosibirsk

Email: klimontov@mail.ru

Russian Federation MD, PhD, Fellow of Russian Academy of Medical Sciences, Director

Vadim Valerievich Klimontov

Research Institute of Clinical and Experimental Lymphology, Novosibirsk

Author for correspondence.
Email: klimontov@mail.ru

Russian Federation MD, PhD, Head of Endocrinology labouratory

Valeriy Vyacheslavovich Chernykh

Novosibirsk Branch of FSBI “The Acad. S.N. Fyodorov Eye Microsurgery Complex”, Novosibirsk

Email: klimontov@mail.ru

Russian Federation доктор медицинских наук, профессор, директор

Nadezhda Viktorovna Tjan

Research Institute of Clinical and Experimental Lymphology, Novosibirsk

Email: klimontov@mail.ru

Russian Federation MD, Researcher assistance in Endocrinology laboratory

  1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564.
  2. doi: 10.2337/dc11-1909.
  3. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):34254.
  4. doi: 10.1007/s11892-012-0283-6.
  5. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1995;113(9):1144–1155.
  6. PMID: 7661748
  7. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008; (1):CD005656.
  8. doi: 10.1002/14651858.CD005656.pub2.
  9. Mohan N, Monickaraj F, Balasubramanyam M, Rema M, Mohan V. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J Diabetes Complications. 2012;26(5):435–441.
  10. doi: 10.1016/j.jdiacomp.2012.05.005.
  11. Ma Y, Zhang Y, Zhao T, Jiang YR. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):307–313.
  12. Schlingemann RO, Van Noorden CJ, Diekman MJ, Tiller A, Meijers JC, Koolwijk P, et al. VEGF Levels in Plasma in Relation to Platelet Activation, Glycemic Control, and Microvascular Complications in Type 1 Diabetes Mellitus. Diabetes Care. 2013;36(6):1629–1634.
  13. doi: 10.2337/dc12-1951.
  14. Бондарь ИА, Климонтов ВВ. Экскреция инсулиноподобного фактора роста 1 и фактора роста эндотелия сосудов с мочой у больных сахарным диабетом 1-го типа с нефропатией. Проблемы эндокринологии. 2007;53(6):3–7.
  15. [Bondar IA, Klimentov VV. Renal excretion of insulin-like growth factor 1 and vascular endothelial growth factor in patients with type 1 diabetes with nephropathy. Problemy Endocrinologii. 2007;53(6):3–7.].
  16. Nicholson BP, Schachat AP. A review of clinical trials of anti-vegf agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):915–930.
  17. doi: 10.1007/S00417-010-1315-Z.
  18. Ford KM, Saint-Geniez M, walshe T, Zahr A, D'Amore PA. Expression and role of vegf in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2011;52(13):9478–9487.
  19. doi: 10.1167/IOVS.11-8353.
  20. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171(1):53–67.
  21. doi: 10.2353/ajpath.2007.061237.
  22. Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, et al. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes. 2007;56(8):2161–2168.
  23. doi: 10.2337/db07-0376.
  24. Errera FI, Canani LH, Silva ME, Yeh E, Takahashi W, Santos KG, et al. Functional vascular endothelial growth factor -634G>C SNP is associated with proliferative diabetic retinopathy: a case-control study in a Brazilian population of European ancestry. Diabetes Care. 2007;30(2):275–279.
  25. doi: 10.2337/dc06-1399.
  26. Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;247(1):21–26.
  27. doi: 10.1007/s00417-008-0915-3.
  28. Yang X, Deng Y, Gu H, Lim A, Altankhuyag A, Jia W, et al. Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis. 2011;17:3088–3096.
  29. PMID: 22162628.
  30. Kоненков ВИ, Шевченко АВ, Прокофьев ВФ, Климонтов ВВ, Королев МА, Фазуллина ОН, и соавт. Ассоциации вариантов гена фактора роста сосудистого эндотелия (VEGF) и генов цитокинов (IL-1В, IL-4, IL-6, IL-10, TNFA) c сахарным диабетом 2 типа у женщин. Сахарный диабет. 2012; (3): 4–10.
  31. [Konenkov V, Shevchenko A, Prokof'ev V, Klimontov V, Korolev M, Fazullina O, Lapsina S, Koroleva E. Associations of vascular endothelial growth factor (VEGF) gene and cytokine (IL1B, IL4, IL6, IL10, TNFA) genescombinations with type 2 diabetes mellitus in women. Diabetes mellitus. 2012;(3):4–10. doi: 10.14341/2072-0351-6079. ]
  32. Коненков ВИ, Шевченко АВ, Прокофьев ВФ, Климонтов ВВ, Королев МА, Фазуллина ОН, и др. Генетические факторы индукции нарушений регуляции ангиогенеза при сахарном диабете 2 типа. Медицинская иммунология. 2012; 14(6): 489–500.
  33. [Konenkov VI, Shevchenko AV, Prokof'ev VF, Klimontov VV, Korolev MA, Fazullina ON, et al. Geneticheskie faktory induktsii narusheniy regulyatsii angiogeneza pri sakharnom diabete 2 tipa. Medizinskaja Immunologia. 2012; 14(6): 489–500.]
  34. Коненков ВИ, Климонтов ВВ. Ангиогенез и васкулогенез при сахарном диабете: новые концепции патогенеза и лечения сосудистых осложнений. Сахарный диабет. 2012;(4):17–27.
  35. [Konenkov V, Klimontov V. Vasculogenesis and angiogenesis in diabetes mellitus: novel pathogenetic concepts for treatment of vascularcomplications. Diabetes mellitus. 2012;(4):17–27. doi: 10.14341/2072-0351-5533. ]
  36. Кузьмин АГ, Смирнова ОМ, Липатов ДВ, Шестакова МВ. Перспективы лечения диабетической ретинопатии: воздействие на фактор роста эндотелия. Сахарный диабет. 2009;(2):33–38.
  37. [Kuzmin A, Smirnova O, Lipatov D, Shestakova M. Prospects for the treatment of diabetic retinopathy: Modulation of endothelial growth factor. Diabetes mellitus. 2009;(2):33–38. doi: 10.14341/2072-0351-5395. ]
  38. Willard AL, Herman IM. Vascular complications and diabetes: current therapies and future challenges. J Ophthalmol. 2012;2012:209538.
  39. doi: 10.1155/2012/209538.
  40. Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4–10.
  41. doi: 10.2174/1874364101307010004.
  42. Puddu A, Sanguineti R, Durante A, Nicolò M, Viviani GL. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization. Mol Vis 2012;18:2509–2517.
  43. PMID: 23112566
  44. Zhong Y, Li J, Chen Y, Wang JJ, Ratan R, Zhang SX. Activation of endoplasmic reticulum stress by hyperglycemia is essential for Müller cell-derived inflammatory cytokine production in diabetes. Diabetes. 2012;61(2):492–504.
  45. doi: 10.2337/db11-0315.
  46. Sun J, Xu Y, Sun S, Sun Y, Wang X. Intermittent high glucose enhances cell proliferation and VEGF expression in retinal endothelial cells: the role of mitochondrial reactive oxygen species. Mol Cell Biochem 2010;343(1–2):27–35.
  47. doi: 10.1007/s11010-010-0495-5.
  48. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001;42(10):2408–2413.
  49. PMID: 11527957
  50. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399–2405.
  51. doi: 10.2337/dc10-0493.
  52. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009;116(11):2175–2181.
  53. doi: 10.1016/j.ophtha.2009.04.023.
  54. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146–2151.
  55. doi: 10.1016/j.ophtha.2010.08.016.
  56. Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, et al. Ranibizumab for edema of the macula in diabetes study 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013;131(2):139–145.
  57. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625.
  58. doi: 10.1016/j.ophtha.2011.01.031.
  59. Network DRCR, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.
  60. doi: 10.1016/j.ophtha.2010.02.031.
  61. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Six-Month Primary End Point Results of a Phase III Study. Ophthalmology 2010;117(6):1124–1133.
  62. doi: 10.1016/j.ophtha.2010.02.022.
  63. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114(4):743–750.
  64. doi: 10.1016/j.ophtha.2006.12.028.
  65. Arevalo JF, Sanchez JG, Fromow-Guerra J, Wu L, Berrocal MH, Farah ME, et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):735–743.
  66. doi: 10.1007/s00417-008-1034-x.
  67. Network DRCR, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A phase II randomized clinical trial of bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860–1867.
  68. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month date: Report 2. Ophthalmology 2010;117(6):1078–1086.
  69. doi: 10.1016/j.ophtha.2010.03.045.
  70. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972–979.
  71. doi: 10.1001/archophthalmol.2012.393.
  72. Zhang Y, Ma J, Meng N, Li H, Qu Y. Comparison of Intravitreal Triamcinolone Acetonide with Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema: A Meta-analysis. Curr Eye Res. 2013;38(5):578–587.
  73. doi: 10.3109/02713683.2013.767351.
  74. Querques G, Bux AV, Martinelli D, Iaculli C, Noci ND. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmol 2009;87(6):623–630.
  75. doi: 10.1111/j.1755-3768.2009.01580.x.
  76. Cunningham ETJr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ,et al , Group MDRS. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112(10):1747–1757.
  77. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS, Group M1S. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011;1018(6):1017–1018.
  78. doi: 10.1016/j.ophtha.2011.02.045.
  79. Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, et al. The DA VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology. 2011;118(9):1819–1826.
  80. doi: 10.1016/j.ophtha.2011.02.018.
  81. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658–1665.
  82. doi: 10.1016/j.ophtha.2012.02.010.
  83. Holz FG, Roider J, Ogura Y, Korobelnik J, Simader C, Groetzbach G, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278–284.
  84. doi: 10.1136/bjophthalmol-2012-301504.
  85. Дедов ИИ, Шестакова МВ, и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (5-й выпуск). Сахарный диабет. 2011;(3s):2–72.
  86. [Dedov I, et al. Algorithms of Specialized Medical Care for Diabetes Mellitus Patients. Diabetes mellitus. 2011;(3s):2–72. doi: 10.14341/2072-0351-5612. ].
  87. Singerman L. Combination therapy using the small interfering RNA bevasiranib. Retina. 2009;29(6Suppl):49–50.
  88. doi: 10.1097/IAE.0b013e3181ad2341.
  89. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97(4):454–459.
  90. doi: 10.1136/bjophthalmol-2012-302451.

Views

Abstract - 1285

PDF (Russian) - 1361

HTML (Russian) - 1464

Cited-By


PlumX


Copyright (c) 2013 Konenkov V.I., Klimontov V.V., Chernykh V.V., Tjan N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.